Y-27632 Dihydrochloride: A Highly Selective ROCK1/2 Inhibitor for Advanced Cell and Disease Modeling

Executive Summary: Y-27632 dihydrochloride is a potent small-molecule inhibitor, targeting ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM, exhibiting >200-fold selectivity against other kinases (APExBIO, product A3008). It disrupts Rho-mediated stress fiber formation, modulates cell cycle progression, and inhibits cytokinesis in vitro (Lei et al. 2025, DOI). Y-27632 enhances stem cell viability and survival in organoid and primary cell culture (internal analyses, Q-VD article). It reduces tumor invasion and metastasis in vivo, providing a valuable tool for cancer biology and regenerative medicine. APExBIO supplies Y-27632 under SKU A3008, supporting high solubility and robust storage protocols (see full product info).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases critical for actin cytoskeleton regulation. They mediate cell shape, motility, and contractility by phosphorylating targets downstream of RhoA GTPase. The Rho/ROCK pathway influences cellular events, including stress fiber formation, cell cycle progression, and cytokinesis. Dysregulation contributes to tumor invasion, metastasis, and impaired stem cell viability. Selective ROCK inhibition enables precise dissection of these pathways in both physiological and pathological contexts. In bovine liver organoid research, modulation of cytoskeletal dynamics is foundational for modeling disease mechanisms (Lei et al. 2025, DOI).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule, cell-permeable inhibitor with high affinity for the catalytic domains of ROCK1 and ROCK2. It competitively binds the ATP-binding site, preventing substrate phosphorylation. The compound demonstrates an IC₅₀ of 140 nM for ROCK1 and a K_i of 300 nM for ROCK2 under in vitro kinase assay conditions (pH 7.4, 25°C). Selectivity profiling shows >200-fold lower activity towards kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK). Inhibiting ROCK disrupts Rho-mediated assembly of actin stress fibers, modulates cell cycle transit from G1 to S phase, and impairs cytokinesis. These effects underpin its utility in studies of cell proliferation, migration, and stem cell survival (APExBIO, product page).

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of 140 nM and ROCK2 with a K_i of 300 nM in biochemical assays (APExBIO product data).
• It shows >200-fold selectivity against PKC, PKA, MLCK, and PAK in kinase panels (APExBIO).
• In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (10–30 µM, 24–72 hr, 37°C, Lei et al. 2025, DOI).
• In vivo mouse models show that Y-27632 reduces tumor invasion and metastasis, with decreased pathological structures in treated tissues (Lei et al. 2025, DOI).
• ROCK inhibition by Y-27632 preserves stem cell viability during organoid establishment and passaging (see Q-VD article).
• Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 25–37°C (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used for:

• Enhancing stem cell viability and passage in 2D/3D cultures, including organoid models.
• Dissecting the Rho/ROCK signaling pathway in cytoskeletal, migration, and proliferation studies.
• Suppressing tumor invasion and metastasis in cancer research models.
• Improving survival rates during primary cell isolation and expansion.

Internal Interlinking: For detailed protocols on organoid and stem cell workflows, see Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Organoid and Cancer Models, which provides actionable protocols—this article extends by providing molecular benchmarks and new animal data. For insight into cytoskeletal regulation and neurodegeneration, Y-27632 Dihydrochloride: Precision ROCK Inhibition for Endo-Lysosomal Dysfunction focuses on neurodegenerative disease applications, whereas here we address broader translational and cancer contexts. For strategic translational recommendations, Redefining Translational Research: Strategic Insights into Rho/ROCK Pathway Modulation offers clinical perspectives; this article details foundational biochemical selectivity.

Common Pitfalls or Misconceptions

• Non-specificity at high concentrations: Above 50 µM, Y-27632 may inhibit kinases beyond ROCK1/2; always validate selectivity under test conditions.
• Not a pan-kinase inhibitor: Y-27632 does NOT broadly inhibit all kinases; it is highly selective for ROCK1/2.
• Does not reverse established fibrosis: While it modulates cytoskeletal dynamics, Y-27632 does not dissolve existing fibrotic tissue in animal models.
• Limited effect in absence of RhoA pathway activity: Cells lacking RhoA-ROCK signaling do not respond to Y-27632.
• Long-term solution storage: Stock solutions are stable at -20°C for months, but working solutions degrade over time—fresh preparation is recommended.

Workflow Integration & Parameters

Y-27632 dihydrochloride (APExBIO A3008) is supplied as a solid. For use, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. Sonication or warming at 37°C improves solubility. Stock solutions should be stored below -20°C, desiccated, and protected from light. Working concentrations in cell culture typically range from 10–30 µM. In organoid establishment, add Y-27632 to media during initial plating and passaging to improve cell survival. Always include vehicle controls to distinguish compound effects. Avoid repeated freeze-thaw cycles. For reproducibility, document batch, solvent, and storage details.

Conclusion & Outlook

Y-27632 dihydrochloride, as supplied by APExBIO, is a robust, highly selective inhibitor of ROCK1/2, enabling precise dissection of the Rho/ROCK pathway in cell biology, stem cell, and cancer research. Its well-characterized selectivity and solubility facilitate reproducible workflows in both basic and translational studies. Ongoing advances in organoid technology and disease modeling continue to expand its relevance. For full specifications, see the Y-27632 dihydrochloride product page.